alglucosidase alfa
Sponsors
Genzyme, a Sanofi Company, Amicus Therapeutics, Taipei Veterans General Hospital, Taiwan
Conditions
Acid Maltase DeficiencyAcid Maltase Deficiency (AMD)Acid Maltase Deficiency DiseaseGlycogen Storage DiseaseGlycogen Storage Disease Type IIGlycogen Storage Disease Type II (GSD II)Glycogen Storage Disease Type II (GSD-II)Glycogenesis 2 Acid Maltase Deficiency
Phase 2
Phase 3
A Placebo-Controlled Study of Safety and Effectiveness of Myozyme (Alglucosidase Alfa) in Patients With Late-Onset Pompe Disease
CompletedNCT00158600
Start: 2005-09-30End: 2007-09-30Updated: 2015-04-28
A Study Comparing ATB200/AT2221 With Alglucosidase Alfa/Placebo in Adult Subjects With Late-onset Pompe Disease
CompletedNCT03729362
Start: 2018-12-04End: 2021-01-15Updated: 2025-09-11
Phase 4
Late-Onset Treatment Study Extension Protocol
CompletedNCT00455195
Start: 2007-03-31End: 2008-11-30Updated: 2014-03-07
High Dose or High Dose Frequency Study of Alglucosidase Alfa
CompletedNCT00483379
Start: 2007-05-31End: 2010-07-31Updated: 2014-03-07
Growth and Development Study of Alglucosidase Alfa
CompletedNCT00486889
Start: 2008-08-26End: 2021-11-23Updated: 2022-08-26
An Exploratory Study of the Safety and Efficacy of Prophylactic Immunomodulatory Treatment in Myozyme-naive Cross-Reacting Immunologic Material (CRIM[-]) Patients With Infantile-Onset Pompe Disease
CompletedNCT00701129
Start: 2009-10-31End: 2013-03-31Updated: 2014-05-13
Exploratory Muscle Biopsy Assessment Study in Patients With Late-Onset Pompe Disease Treated With Alglucosidase Alfa
CompletedNCT01288027
Start: 2011-06-30End: 2013-12-31Updated: 2014-12-19
Pharmacokinetics of Alglucosidase Alfa in Patients With Pompe Disease
CompletedNCT01410890
Start: 2014-11-03End: 2020-11-20Updated: 2022-03-28
A Study to Evaluate the Efficacy and Safety of Alglucosidase Alfa Produced at the 4000 L Scale for Pompe Disease
TerminatedNCT01526785
Start: 2012-03-31End: 2014-12-31Updated: 2015-12-08
A Noninferiority Study of Alglucosidase Alfa Manufactured at the 160 L and 4000 L Scales in Treatment Naïve Patients With Infantile-Onset Pompe Disease
TerminatedNCT01597596
Start: 2012-08-31End: 2014-12-31Updated: 2016-01-18
Study to Evaluate Efficacy and Safety in Chinese Patients With Late Onset Pompe Disease With Alglucosidase Alfa Treatmen
CompletedNCT04676373
Start: 2021-03-10End: 2024-07-25Updated: 2025-02-10
Unknown Phase
Expanded Access Use of Myozyme (Alglucosidase Alfa) in Patients With Infantile-onset Pompe Disease
NCT00074919
Start: 2003-12-31End: 2007-02-28Updated: 2014-02-05
Pompe Lactation Sub-Registry
CompletedNCT00566878
Start: 2012-03-31End: 2024-02-09Updated: 2024-03-19
Alglucosidase Alfa Pompe Safety Sub-Registry
CompletedNCT01710813
Start: 2015-03-20End: 2021-04-20Updated: 2021-07-13
Higher Dose of Alglucosidase Alpha for Pompe Disease
Not yet recruitingNCT05017402
Start: 2021-09-01End: 2026-12-31Target: 36Updated: 2021-08-23
Related Papers
2 more papers not shown